Johanna T. W. Snijkers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johanna T. W. Snijkers has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Keszthelyi
Institute of Nutrition and Translational Research in Metabolism (NUTRIM) Maastricht University Maastricht the Netherlands
10 shared publications - Adrian A. M. Masclee
Department of Gastroenterology – Hepatology, School of Nutrition and Translational Research in Metabolism (NUTRIM) Maastricht University Medical Center Maastricht the Netherlands
6 shared publications - Zsa Zsa Regina Maria Weerts
Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands
5 shared publications - Abraham Bèr Beckers
Department of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, the Netherlands; NUTRIM school of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands
3 shared publications - Bjorn Winkens
Department of Methodology and Statistics, Maastricht University Medical Center+, Debyelaan 25, 6229 HX Maastricht, The Netherlands
3 shared publications - Lisa Vork
Department of Gastroenterology and Hepatology Maastricht University Medical Center Maastricht the Netherlands
3 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7)
Characterising the Economic Burden of Functional Dyspepsia: A Cost‐of‐Illness Study of Direct and Indirect Costs
Background: Functional dyspepsia (FD) is a prevalent disorder of gut‐brain interaction (DGBI) and is associated with substantial impact on health care utilisation. However, analyses examining patient‐specific characteristics that contribute to this burden remain limited. This study assessed the economic burden of patients with FD and examined patient‐specific characteristics related to costs. Methods: Patients who had been recruited for a randomised controlled trial completed several questionnaires. Health care utilisation and productivity losses were measured using the iMTA Medical Consumption Questionnaire and Productivity Cost Questionnaire. Participants also completed the EuroQol 5‐Dimension 5‐Level, Nepean Dyspepsia Index, Generalised Anxiety Disorder‐7, and Patient Health Questionnaire‐9. Non‐parametric bootstrapping was applied to calculate the mean annual costs. Multivariable linear regression was used to identify patient‐specific characteristics associated with costs. Results: Data were obtained from 73 participants (median age 39 years; 75% female). Mean annual total costs accounted for €12,192 (2.5th to 97.5th percentiles, €1125 to €36,369), of which €10,240 (2.5th to 97.5th percentiles, €0 to €34,771) were indirect costs. Higher disease‐specific quality of life (QoL) was associated with lower annual total costs (regression slope = −€4726 per 0.1‐point increase in QoL; 95% CI, −€7636 to −€1815; p = 0.002), while symptom severity, generic health‐related QoL or scores for anxiety or depression were not significantly associated. Conclusion: Patients with poorer disease‐specific QoL, but not necessarily those with more severe symptoms or higher scores for anxiety and depression, are particularly likely to incur higher annual costs. Understanding the nature of costs and associated patient characteristics is essential for enabling more targeted strategies. Trial Registration: The TENDER trial was registered on Clinicaltrials.gov under NCT03652571 on August 17, 2018.
- 30 July 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7)
Open AccessCharacterising the Economic Burden of Functional Dyspepsia: A Cost‐of‐Illness Study of Direct and Indirect Costs
Background: Functional dyspepsia (FD) is a prevalent disorder of gut‐brain interaction (DGBI) and is associated with substantial impact on health care utilisation. However, analyses examining patient‐specific characteristics that contribute to this burden remain limited. This study assessed the economic burden of patients with FD and examined patient‐specific characteristics related to costs. Methods: Patients who had been recruited for a randomised controlled trial completed several questionnaires. Health care utilisation and productivity losses were measured using the iMTA Medical Consumption Questionnaire and Productivity Cost Questionnaire. Participants also completed the EuroQol 5‐Dimension 5‐Level, Nepean Dyspepsia Index, Generalised Anxiety Disorder‐7, and Patient Health Questionnaire‐9. Non‐parametric bootstrapping was applied to calculate the mean annual costs. Multivariable linear regression was used to identify patient‐specific characteristics associated with costs. Results: Data were obtained from 73 participants (median age 39 years; 75% female). Mean annual total costs accounted for €12,192 (2.5th to 97.5th percentiles, €1125 to €36,369), of which €10,240 (2.5th to 97.5th percentiles, €0 to €34,771) were indirect costs. Higher disease‐specific quality of life (QoL) was associated with lower annual total costs (regression slope = −€4726 per 0.1‐point increase in QoL; 95% CI, −€7636 to −€1815; p = 0.002), while symptom severity, generic health‐related QoL or scores for anxiety or depression were not significantly associated. Conclusion: Patients with poorer disease‐specific QoL, but not necessarily those with more severe symptoms or higher scores for anxiety and depression, are particularly likely to incur higher annual costs. Understanding the nature of costs and associated patient characteristics is essential for enabling more targeted strategies. Trial Registration: The TENDER trial was registered on Clinicaltrials.gov under NCT03652571 on August 17, 2018.
- Top Cited PapersOpen Access
In-person therapist-delivered hypnotherapy versus smartphone-based self-guided hypnotherapy in IBS: a multicentre three-armed randomised controlled trial
Background: Hypnotherapy is an evidence-based therapy recommended for IBS, but access to therapist-led hypnotherapy is limited by costs and availability. Objective: We studied the effectiveness of smartphone-based self-guided hypnotherapy versus in-person therapist-delivered hypnotherapy. Design: This multicentre, three-armed non-inferiority randomised controlled trial (RCT) included patients with IBS (Rome IV, 16–75 years). Patients were randomised to 12-week in-person therapist-delivered hypnotherapy, smartphone-based self-guided hypnotherapy or online self-guided psychoeducation. The primary endpoint was abdominal pain response per Food and Drug Administration (FDA) definition (≥30% reduction from baseline in weekly average of worst daily abdominal pain in at least 2 out of 4 weeks follow-up). The non-inferiority margin was 10%. Secondary endpoints included ≥50 points IBS-symptom severity scale reduction and changes in psychological symptoms. Results: A total of 230 patients (mean±SD age 38.2±13.8 years, 70.4% female) were randomised. FDA abdominal pain response rates were 48% for in-person therapist-delivered hypnotherapy, 33% for smartphone-based self-guided hypnotherapy and 22% for psychoeducation. Non-inferiority of online to in-person hypnotherapy could not be shown (−14.7%, 95% CI −29.3% to 0.9%). In-person hypnotherapy was more effective than psychoeducation (OR 3.48, 95% CI 1.68 to 7.20, p<0.001) at week 16, both hypnotherapy groups were more effective at 6-month follow-up (OR 3.11, 95% CI 1.37 to 7.09, p=0.007 and OR 4.68, 95% CI 2.07 to 10.57, p<0.001). There were no significant treatment effects on psychological symptoms between groups. Conclusion: This multicentre RCT could not demonstrate non-inferiority of smartphone-based self-guided hypnotherapy compared with in-person therapist-delivered hypnotherapy in reducing abdominal pain. However, substantial response rates for smartphone-based self-guided hypnotherapy highlight its potential as a broadly applicable and cost-effective alternative. Trial registration number: NCT03899779 .
Top Cited PapersOpen AccessIn-person therapist-delivered hypnotherapy versus smartphone-based self-guided hypnotherapy in IBS: a multicentre three-armed randomised controlled trial
Background: Hypnotherapy is an evidence-based therapy recommended for IBS, but access to therapist-led hypnotherapy is limited by costs and availability. Objective: We studied the effectiveness of smartphone-based self-guided hypnotherapy versus in-person therapist-delivered hypnotherapy. Design: This multicentre, three-armed non-inferiority randomised controlled trial (RCT) included patients with IBS (Rome IV, 16–75 years). Patients were randomised to 12-week in-person therapist-delivered hypnotherapy, smartphone-based self-guided hypnotherapy or online self-guided psychoeducation. The primary endpoint was abdominal pain response per Food and Drug Administration (FDA) definition (≥30% reduction from baseline in weekly average of worst daily abdominal pain in at least 2 out of 4 weeks follow-up). The non-inferiority margin was 10%. Secondary endpoints included ≥50 points IBS-symptom severity scale reduction and changes in psychological symptoms. Results: A total of 230 patients (mean±SD age 38.2±13.8 years, 70.4% female) were randomised. FDA abdominal pain response rates were 48% for in-person therapist-delivered hypnotherapy, 33% for smartphone-based self-guided hypnotherapy and 22% for psychoeducation. Non-inferiority of online to in-person hypnotherapy could not be shown (−14.7%, 95% CI −29.3% to 0.9%). In-person hypnotherapy was more effective than psychoeducation (OR 3.48, 95% CI 1.68 to 7.20, p<0.001) at week 16, both hypnotherapy groups were more effective at 6-month follow-up (OR 3.11, 95% CI 1.37 to 7.09, p=0.007 and OR 4.68, 95% CI 2.07 to 10.57, p<0.001). There were no significant treatment effects on psychological symptoms between groups. Conclusion: This multicentre RCT could not demonstrate non-inferiority of smartphone-based self-guided hypnotherapy compared with in-person therapist-delivered hypnotherapy in reducing abdominal pain. However, substantial response rates for smartphone-based self-guided hypnotherapy highlight its potential as a broadly applicable and cost-effective alternative. Trial registration number: NCT03899779 .
- Top Cited PapersOpen Access
- 29 January 2026
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (8) , 2273-2285
Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-blind, Placebo-controlled Trial
- 29 January 2026
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (8) , 2273-2285
Top Cited PapersOpen AccessTailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-blind, Placebo-controlled Trial
- Open Access
- 23 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (5) , 1098-1107
Results From a Psychometric Validation Study: Patients With Irritable Bowel Syndrome Report Higher Symptom Burden Using End-of-Day Vs Real-Time Assessment
INTRODUCTION: Real-time assessment of gastrointestinal (GI) symptoms in irritable bowel syndrome (IBS) using the experience sampling method (ESM) is suggested as a more appropriate approach than currently used end-of-day or end-of-week reports. This psychometric evaluation study assesses the validity and reliability of a previously developed ESM-based patient-reported outcome measure (PROM) for real-time GI symptom assessment in IBS. METHODS: This multicenter validation study included 230 Rome IV patients with IBS (80% female; mean age 41.2 years) in 3 European countries. Patients completed the electronic ESM-PROM (up to 10 random moments daily, with a weekly minimum completion rate of 33%) and an end-of-day symptom diary for 7 consecutive days. End-of-week questionnaires (Gastrointestinal Symptom Rating Scale for IBS, IBS Severity Scoring System, Patient Health Questionnaire-9, and Generalized Anxiety Disorder-7) were completed at the end of the 7-day period. RESULTS: The ESM assessment had a mean completion rate of 71%. Strong and significant correlations (0.651–0.956) with moderate-to-good consistency (intra-class correlation coefficients 0.580–0.779) were observed between ESM and end-of-day scores. However, end-of-day scores were significantly higher (Δ0.790–1.758, P < 0.001) than mean daily ESM scores. Differences with end-of-week scores were more pronounced, with weaker correlations (Pearson's r 0.393–0.802). ESM-PROM exhibited moderate-to-good internal consistency (Cronbach's α 0.585–0.887) across 5 symptom domains. First and second half-week scores demonstrated good-to-excellent consistency (intraclass correlation coefficients 0.871–0.958). DISCUSSION: Psychometric evaluation demonstrated strong validity and reliability of the ESM-PROM for real-time GI symptom assessment in IBS. In addition, the ESM-PROM provides a precise and reliable ascertainment of individual symptom pattern and trigger interactions, without the bias of peak reporting when compared with retrospective methods. This highlights its potential as a valuable tool for personalized healthcare in monitoring disease course and treatment response in patients with IBS.
- 23 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (5) , 1098-1107
Open AccessResults From a Psychometric Validation Study: Patients With Irritable Bowel Syndrome Report Higher Symptom Burden Using End-of-Day Vs Real-Time Assessment
INTRODUCTION: Real-time assessment of gastrointestinal (GI) symptoms in irritable bowel syndrome (IBS) using the experience sampling method (ESM) is suggested as a more appropriate approach than currently used end-of-day or end-of-week reports. This psychometric evaluation study assesses the validity and reliability of a previously developed ESM-based patient-reported outcome measure (PROM) for real-time GI symptom assessment in IBS. METHODS: This multicenter validation study included 230 Rome IV patients with IBS (80% female; mean age 41.2 years) in 3 European countries. Patients completed the electronic ESM-PROM (up to 10 random moments daily, with a weekly minimum completion rate of 33%) and an end-of-day symptom diary for 7 consecutive days. End-of-week questionnaires (Gastrointestinal Symptom Rating Scale for IBS, IBS Severity Scoring System, Patient Health Questionnaire-9, and Generalized Anxiety Disorder-7) were completed at the end of the 7-day period. RESULTS: The ESM assessment had a mean completion rate of 71%. Strong and significant correlations (0.651–0.956) with moderate-to-good consistency (intra-class correlation coefficients 0.580–0.779) were observed between ESM and end-of-day scores. However, end-of-day scores were significantly higher (Δ0.790–1.758, P < 0.001) than mean daily ESM scores. Differences with end-of-week scores were more pronounced, with weaker correlations (Pearson's r 0.393–0.802). ESM-PROM exhibited moderate-to-good internal consistency (Cronbach's α 0.585–0.887) across 5 symptom domains. First and second half-week scores demonstrated good-to-excellent consistency (intraclass correlation coefficients 0.871–0.958). DISCUSSION: Psychometric evaluation demonstrated strong validity and reliability of the ESM-PROM for real-time GI symptom assessment in IBS. In addition, the ESM-PROM provides a precise and reliable ascertainment of individual symptom pattern and trigger interactions, without the bias of peak reporting when compared with retrospective methods. This highlights its potential as a valuable tool for personalized healthcare in monitoring disease course and treatment response in patients with IBS.
- Open Access
- 4 October 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (3) , 512-520
Satisfaction With Life in IBS Is Associated With Psychological Burden Rather than Gastrointestinal Symptom Severity
INTRODUCTION: Irritable bowel syndrome (IBS) has a major impact on emotional, social, and professional life. This study aimed to evaluate general life satisfaction, a subjective measure of well-being, in IBS patients, and to determine which factors are associated with higher life satisfaction. METHODS: IBS patients (n = 195, mean age 51.4 ± 16.5 years, 73.8% female) recruited from primary and secondary/tertiary care completed questionnaires regarding gastrointestinal symptoms, quality of life, psychological factors, and life satisfaction (Satisfaction With Life Scale, 5 items, range 5–35). A finite mixture model analysis was performed to identify latent classes. Multivariable linear regression was used to identify variables associated with life satisfaction. RESULTS: Overall, 71.3% of the patients were satisfied about their life (Satisfaction With Life Scale-score ≥21). Three latent subgroups could be identified with significantly higher life satisfaction in the subgroup with higher mental quality of life, fewer anxiety and depressive symptoms, lower gastrointestinal specific anxiety, and lower gastrointestinal symptom severity, compared with the other 2 groups. Multivariable linear regression showed that higher physical quality of life (B0.168, P < 0.001) and higher mental quality of life (B0.199, P < 0.001) were associated with higher life satisfaction. Using multivariable regression, no significant association was found between gastrointestinal symptom severity and life satisfaction. DISCUSSION: Higher physical and mental quality of life, but not gastrointestinal symptom severity, were independently associated with higher general life satisfaction in IBS. These findings reinforce the clinical need in IBS treatment to focus on the full extent of the disorder and not merely on gastrointestinal symptom improvement. ClinicalTrials.gov Identifier: NCT00775060.
- 4 October 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (3) , 512-520
Open AccessSatisfaction With Life in IBS Is Associated With Psychological Burden Rather than Gastrointestinal Symptom Severity
INTRODUCTION: Irritable bowel syndrome (IBS) has a major impact on emotional, social, and professional life. This study aimed to evaluate general life satisfaction, a subjective measure of well-being, in IBS patients, and to determine which factors are associated with higher life satisfaction. METHODS: IBS patients (n = 195, mean age 51.4 ± 16.5 years, 73.8% female) recruited from primary and secondary/tertiary care completed questionnaires regarding gastrointestinal symptoms, quality of life, psychological factors, and life satisfaction (Satisfaction With Life Scale, 5 items, range 5–35). A finite mixture model analysis was performed to identify latent classes. Multivariable linear regression was used to identify variables associated with life satisfaction. RESULTS: Overall, 71.3% of the patients were satisfied about their life (Satisfaction With Life Scale-score ≥21). Three latent subgroups could be identified with significantly higher life satisfaction in the subgroup with higher mental quality of life, fewer anxiety and depressive symptoms, lower gastrointestinal specific anxiety, and lower gastrointestinal symptom severity, compared with the other 2 groups. Multivariable linear regression showed that higher physical quality of life (B0.168, P < 0.001) and higher mental quality of life (B0.199, P < 0.001) were associated with higher life satisfaction. Using multivariable regression, no significant association was found between gastrointestinal symptom severity and life satisfaction. DISCUSSION: Higher physical and mental quality of life, but not gastrointestinal symptom severity, were independently associated with higher general life satisfaction in IBS. These findings reinforce the clinical need in IBS treatment to focus on the full extent of the disorder and not merely on gastrointestinal symptom improvement. ClinicalTrials.gov Identifier: NCT00775060.
- Open Access
- 24 November 2021
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 5 (11) , e31678
Digital Instruments for Reporting of Gastrointestinal Symptoms in Clinical Trials: Comparison of End-of-Day Diaries Versus the Experience Sampling Method
Background: Questionnaires are necessary tools for assessing symptoms of disorders of the brain-gut interaction in clinical trials. We previously reported on the excellent adherence to a smartphone app used as symptom diary in a randomized clinical trial on irritable bowel syndrome (IBS). Other sampling methods, such as the experience sampling method (ESM), are better equipped to measure symptom variability over time and provide useful information regarding possible symptom triggers, and they are free of ecological and recall bias. The high frequency of measurements, however, could limit the feasibility of ESM in clinical trials. Objective: This study aimed to compare the adherence rates of a smartphone-based end-of-day diary and ESM for symptom assessment in IBS and functional dyspepsia (FD). Methods: Data from 4 separate studies were included. Patients with IBS participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+8-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Patients with FD participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+12-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Adherence rates were compared between these 2 symptom sampling methods. Results: In total, 25 patients with IBS and 15 patients with FD were included. Overall adherence rates for the end-of-day diaries were significantly higher than those for ESM (IBS: 92.7% vs 69.8%, FD: 90.1% vs 61.4%, respectively). Conclusions: This study demonstrates excellent adherence rates for smartphone app–based end-of-day diaries as used in 2 separate clinical trials. Overall adherence rates for ESM were significantly lower, rendering it more suitable for intermittent sampling periods rather than continuous sampling during longer clinical trials.
- 24 November 2021
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 5 (11) , e31678
Open AccessDigital Instruments for Reporting of Gastrointestinal Symptoms in Clinical Trials: Comparison of End-of-Day Diaries Versus the Experience Sampling Method
Background: Questionnaires are necessary tools for assessing symptoms of disorders of the brain-gut interaction in clinical trials. We previously reported on the excellent adherence to a smartphone app used as symptom diary in a randomized clinical trial on irritable bowel syndrome (IBS). Other sampling methods, such as the experience sampling method (ESM), are better equipped to measure symptom variability over time and provide useful information regarding possible symptom triggers, and they are free of ecological and recall bias. The high frequency of measurements, however, could limit the feasibility of ESM in clinical trials. Objective: This study aimed to compare the adherence rates of a smartphone-based end-of-day diary and ESM for symptom assessment in IBS and functional dyspepsia (FD). Methods: Data from 4 separate studies were included. Patients with IBS participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+8-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Patients with FD participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+12-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Adherence rates were compared between these 2 symptom sampling methods. Results: In total, 25 patients with IBS and 15 patients with FD were included. Overall adherence rates for the end-of-day diaries were significantly higher than those for ESM (IBS: 92.7% vs 69.8%, FD: 90.1% vs 61.4%, respectively). Conclusions: This study demonstrates excellent adherence rates for smartphone app–based end-of-day diaries as used in 2 separate clinical trials. Overall adherence rates for ESM were significantly lower, rendering it more suitable for intermittent sampling periods rather than continuous sampling during longer clinical trials.
- Open Access
- 23 November 2021
- Published by Springer Nature in BMC Gastroenterology
- Vol. 21 (1) , 1-8
Patient preferences of healthcare delivery in irritable bowel syndrome: a focus group study
Background: Irritable bowel syndrome (IBS) is a highly prevalent disorder with significant negative impact on quality of life of patients that results in high healthcare use and costs. Improving healthcare outcomes for IBS patients is warranted, however the exact needs of IBS patients with regard to therapy and control of symptoms are unknown. Methods: Focus group interviews, using a two-stage model, were performed with twenty-three IBS patients meeting Rome III criteria and one mother of a patient, from four different regions from the Netherlands. Results: Twenty-four participants were included of whom majority were female (n = 21), mean age was 43 years, and mean duration of IBS was 18 years. Five categories of patients’ perspectives were identified: clear communication, a multidisciplinary treatment team, centers of expertise, focus on scientific research and information about IBS that is widely available for patients. Conclusions: Based on these findings we highlight the need for IBS care givers to take these key items into account in IBS care. These elements aid clinicians, but mostly patients, in coping and management of symptoms and subsequent healthcare outcomes, reducing overall healthcare use and costs.
- 23 November 2021
- Published by Springer Nature in BMC Gastroenterology
- Vol. 21 (1) , 1-8
Open AccessPatient preferences of healthcare delivery in irritable bowel syndrome: a focus group study
Background: Irritable bowel syndrome (IBS) is a highly prevalent disorder with significant negative impact on quality of life of patients that results in high healthcare use and costs. Improving healthcare outcomes for IBS patients is warranted, however the exact needs of IBS patients with regard to therapy and control of symptoms are unknown. Methods: Focus group interviews, using a two-stage model, were performed with twenty-three IBS patients meeting Rome III criteria and one mother of a patient, from four different regions from the Netherlands. Results: Twenty-four participants were included of whom majority were female (n = 21), mean age was 43 years, and mean duration of IBS was 18 years. Five categories of patients’ perspectives were identified: clear communication, a multidisciplinary treatment team, centers of expertise, focus on scientific research and information about IBS that is widely available for patients. Conclusions: Based on these findings we highlight the need for IBS care givers to take these key items into account in IBS care. These elements aid clinicians, but mostly patients, in coping and management of symptoms and subsequent healthcare outcomes, reducing overall healthcare use and costs.
- Open Access
- 30 June 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Digital Instruments for Reporting of Gastrointestinal Symptoms in Clinical Trials: Comparison of End-of-Day Diaries Versus the Experience Sampling Method (Preprint)
BACKGROUND Questionnaires are necessary tools for assessing symptoms of disorders of the brain-gut interaction in clinical trials. We previously reported on the excellent adherence to a smartphone app used as symptom diary in a randomized clinical trial on irritable bowel syndrome (IBS). Other sampling methods, such as the experience sampling method (ESM), are better equipped to measure symptom variability over time and provide useful information regarding possible symptom triggers, and they are free of ecological and recall bias. The high frequency of measurements, however, could limit the feasibility of ESM in clinical trials. OBJECTIVE This study aimed to compare the adherence rates of a smartphone-based end-of-day diary and ESM for symptom assessment in IBS and functional dyspepsia (FD). METHODS Data from 4 separate studies were included. Patients with IBS participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+8-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Patients with FD participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+12-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Adherence rates were compared between these 2 symptom sampling methods. RESULTS In total, 25 patients with IBS and 15 patients with FD were included. Overall adherence rates for the end-of-day diaries were significantly higher than those for ESM (IBS: 92.7% vs 69.8%, FD: 90.1% vs 61.4%, respectively). CONCLUSIONS This study demonstrates excellent adherence rates for smartphone app–based end-of-day diaries as used in 2 separate clinical trials. Overall adherence rates for ESM were significantly lower, rendering it more suitable for intermittent sampling periods rather than continuous sampling during longer clinical trials.
- 30 June 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDigital Instruments for Reporting of Gastrointestinal Symptoms in Clinical Trials: Comparison of End-of-Day Diaries Versus the Experience Sampling Method (Preprint)
BACKGROUND Questionnaires are necessary tools for assessing symptoms of disorders of the brain-gut interaction in clinical trials. We previously reported on the excellent adherence to a smartphone app used as symptom diary in a randomized clinical trial on irritable bowel syndrome (IBS). Other sampling methods, such as the experience sampling method (ESM), are better equipped to measure symptom variability over time and provide useful information regarding possible symptom triggers, and they are free of ecological and recall bias. The high frequency of measurements, however, could limit the feasibility of ESM in clinical trials. OBJECTIVE This study aimed to compare the adherence rates of a smartphone-based end-of-day diary and ESM for symptom assessment in IBS and functional dyspepsia (FD). METHODS Data from 4 separate studies were included. Patients with IBS participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+8-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Patients with FD participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+12-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Adherence rates were compared between these 2 symptom sampling methods. RESULTS In total, 25 patients with IBS and 15 patients with FD were included. Overall adherence rates for the end-of-day diaries were significantly higher than those for ESM (IBS: 92.7% vs 69.8%, FD: 90.1% vs 61.4%, respectively). CONCLUSIONS This study demonstrates excellent adherence rates for smartphone app–based end-of-day diaries as used in 2 separate clinical trials. Overall adherence rates for ESM were significantly lower, rendering it more suitable for intermittent sampling periods rather than continuous sampling during longer clinical trials.
- Open Access
- 3 May 2021
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 33 (12) , e14161
Examining the optimal cutoff values of HADS, PHQ‐9 and GAD‐7 as screening instruments for depression and anxiety in irritable bowel syndrome
Background: Self‐rating scales are frequently used to screen for anxiety and depression in patients with irritable bowel syndrome (IBS). Different cutoff values are recommended in literature, and guidelines have suggested the use of other screening instruments over time. The aim of this study was to assess the correlation between the most commonly used psychological screening instruments for anxiety and depression in IBS and to compare custom cutoff scores for these instruments.Methods: Irritable bowel syndrome patients (n = 192) completed several questionnaires including the Hospital Anxiety and Depression Scale (HADS, HADS‐A and HADS‐D subscale), Patient Health Questionnaire‐9 (PHQ‐9) and Generalized Anxiety Disorder‐7 (GAD‐7). Agreement at different cutoff points, for depressive and anxiety disorder, was assessed by use of the Gwet AC1 coefficient.Key Results: Hospital Anxiety and Depression Scale (HADS)‐D and PHQ‐9 scores, and HADS‐A and GAD‐7 scores showed high correlations (rs = 0.735 and rs = 0.805, respectively). For depressive disorder, a Gwet AC1 value of 0.829 was found when recommended cutoff points from literature were compared (PHQ‐9 cutoff ≥10, HADS‐D cutoff ≥8). For anxiety disorder, a Gwet AC1 value of 0.806 was found when recommended cutoff points from literature were compared (GAD‐7 cutoff ≥10, HADS‐A cutoff ≥8). Even higher agreements were found when higher HADS cutoff values were chosen, with impact on sensitivity and specificity.Conclusions & Inferences: Custom cutoff values deem the HADS subscales (HADS‐D and HADS‐A) concordant to PHQ‐9 and GAD‐7 scores. The choice of a cutoff value has substantial impact on sensitivity/specificity and is dependent on patient population, setting, and the purpose of use.
- 3 May 2021
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 33 (12) , e14161
Open AccessExamining the optimal cutoff values of HADS, PHQ‐9 and GAD‐7 as screening instruments for depression and anxiety in irritable bowel syndrome
Background: Self‐rating scales are frequently used to screen for anxiety and depression in patients with irritable bowel syndrome (IBS). Different cutoff values are recommended in literature, and guidelines have suggested the use of other screening instruments over time. The aim of this study was to assess the correlation between the most commonly used psychological screening instruments for anxiety and depression in IBS and to compare custom cutoff scores for these instruments.Methods: Irritable bowel syndrome patients (n = 192) completed several questionnaires including the Hospital Anxiety and Depression Scale (HADS, HADS‐A and HADS‐D subscale), Patient Health Questionnaire‐9 (PHQ‐9) and Generalized Anxiety Disorder‐7 (GAD‐7). Agreement at different cutoff points, for depressive and anxiety disorder, was assessed by use of the Gwet AC1 coefficient.Key Results: Hospital Anxiety and Depression Scale (HADS)‐D and PHQ‐9 scores, and HADS‐A and GAD‐7 scores showed high correlations (rs = 0.735 and rs = 0.805, respectively). For depressive disorder, a Gwet AC1 value of 0.829 was found when recommended cutoff points from literature were compared (PHQ‐9 cutoff ≥10, HADS‐D cutoff ≥8). For anxiety disorder, a Gwet AC1 value of 0.806 was found when recommended cutoff points from literature were compared (GAD‐7 cutoff ≥10, HADS‐A cutoff ≥8). Even higher agreements were found when higher HADS cutoff values were chosen, with impact on sensitivity and specificity.Conclusions & Inferences: Custom cutoff values deem the HADS subscales (HADS‐D and HADS‐A) concordant to PHQ‐9 and GAD‐7 scores. The choice of a cutoff value has substantial impact on sensitivity/specificity and is dependent on patient population, setting, and the purpose of use.
- 1 January 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (1) , 123-136
Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome
- 1 January 2020
- Published by Elsevier in Gastroenterology
- Vol. 158 (1) , 123-136
Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome